MAPT and Alzheimer disease: Methylthioninium chloride (MTC; commonly known as “methylene blue”), the first reported TAI, reverses the proteolytic stability of PHFs isolated from AD brain tissues in vitro without disrupting normal Tau-tubulin interactions (9).